An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
    • Publication Information:
      Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
      Original Publication: New Haven [etc.] American Society for Clinical Investigation.
    • Subject Terms:
      Apolipoproteins E/*metabolism ; Bone Morphogenetic Protein Receptors, Type II/*metabolism ; Bone Morphogenetic Proteins/*metabolism ; Hypertension, Pulmonary/*metabolism ; Myocytes, Smooth Muscle/*metabolism ; PPAR gamma/*metabolism ; Transforming Growth Factor beta/*metabolism; Animals ; Apolipoproteins E/genetics ; Becaplermin ; Bone Morphogenetic Protein 2 ; Bone Morphogenetic Protein Receptors, Type II/genetics ; Bone Morphogenetic Proteins/genetics ; Cells, Cultured ; Extracellular Signal-Regulated MAP Kinases/genetics ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Hemodynamics ; Humans ; Hypertension, Pulmonary/physiopathology ; Hypoglycemic Agents/metabolism ; Mice ; Mice, Knockout ; Mice, Transgenic ; Muscle, Smooth, Vascular/cytology ; Muscle, Smooth, Vascular/metabolism ; Myocytes, Smooth Muscle/cytology ; PPAR gamma/genetics ; Platelet-Derived Growth Factor/metabolism ; Proto-Oncogene Proteins c-sis ; RNA Interference ; Rosiglitazone ; Signal Transduction/physiology ; Thiazolidinediones/metabolism ; Transforming Growth Factor beta/genetics
    • Abstract:
      Loss-of-function mutations in bone morphogenetic protein receptor II (BMP-RII) are linked to pulmonary arterial hypertension (PAH); the ligand for BMP-RII, BMP-2, is a negative regulator of SMC growth. Here, we report an interplay between PPARgamma and its transcriptional target apoE downstream of BMP-2 signaling. BMP-2/BMP-RII signaling prevented PDGF-BB-induced proliferation of human and murine pulmonary artery SMCs (PASMCs) by decreasing nuclear phospho-ERK and inducing DNA binding of PPARgamma that is independent of Smad1/5/8 phosphorylation. Both BMP-2 and a PPARgamma agonist stimulated production and secretion of apoE by SMCs. Using a variety of methods, including short hairpin RNAi in human PASMCs, PAH patient-derived BMP-RII mutant PASMCs, a PPARgamma antagonist, and PASMCs isolated from PPARgamma- and apoE-deficient mice, we demonstrated that the antiproliferative effect of BMP-2 was BMP-RII, PPARgamma, and apoE dependent. Furthermore, we created mice with targeted deletion of PPARgamma in SMCs and showed that they spontaneously developed PAH, as indicated by elevated RV systolic pressure, RV hypertrophy, and increased muscularization of the distal pulmonary arteries. Thus, PPARgamma-mediated events could protect against PAH, and PPARgamma agonists may reverse PAH in patients with or without BMP-RII dysfunction.
    • References:
      Science. 2003 Apr 11;300(5617):329-32. (PMID: 12690199)
      J Biol Chem. 2000 Jul 21;275(29):22435-41. (PMID: 10801895)
      Eur Respir J. 2002 Sep;20(3):518-23. (PMID: 12358323)
      Am J Hum Genet. 2000 Sep;67(3):737-44. (PMID: 10903931)
      J Cardiovasc Pharmacol. 2002 Dec;40(6):822-31. (PMID: 12451315)
      FEBS Lett. 2003 Aug 28;550(1-3):107-13. (PMID: 12935895)
      Arterioscler Thromb Vasc Biol. 2000 Apr;20(4):1020-6. (PMID: 10764667)
      Kidney Int. 2003 Jul;64(1):52-62. (PMID: 12787395)
      Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54. (PMID: 16446752)
      Circ Res. 2006 Apr 14;98(7):e50-9. (PMID: 16556873)
      FASEB J. 2000 Apr;14(5):805-14. (PMID: 10744637)
      Circulation. 2002 Jun 18;105(24):2893-8. (PMID: 12070119)
      Biochem Biophys Res Commun. 2002 Oct 18;298(1):128-32. (PMID: 12379230)
      Arterioscler Thromb Vasc Biol. 2004 May;24(5):935-42. (PMID: 14988091)
      J Am Coll Cardiol. 2004 Jun 16;43(12 Suppl S):33S-39S. (PMID: 15194176)
      Arterioscler Thromb Vasc Biol. 2005 Jul;25(7):1414-8. (PMID: 15860741)
      J Biol Chem. 2002 Feb 8;277(6):4062-8. (PMID: 11733495)
      Biochemistry. 2002 Oct 1;41(39):11820-3. (PMID: 12269825)
      Circulation. 2002 Apr 9;105(14):1672-8. (PMID: 11940546)
      J Cardiovasc Pharmacol. 2001 Dec;38(6):909-21. (PMID: 11707695)
      Biochemistry. 1990 Jun 19;29(24):5783-9. (PMID: 2383557)
      Nat Med. 2000 Jun;6(6):698-702. (PMID: 10835689)
      Mol Cell Biol. 2002 Apr;22(8):2607-19. (PMID: 11909955)
      J Clin Invest. 1997 Dec 1;100(11):2824-32. (PMID: 9389748)
      Circulation. 2005 Jul 19;112(3):423-31. (PMID: 16027270)
      Circ Res. 2004 May 14;94(9):1168-78. (PMID: 15142970)
      Eur Respir J. 2004 Sep;24(3):371-4. (PMID: 15358693)
      Am J Respir Cell Mol Biol. 2007 Nov;37(5):598-605. (PMID: 17600318)
      Nat Med. 2003 Dec;9(12):1491-7. (PMID: 14625542)
      Circulation. 2007 Mar 13;115(10):1275-84. (PMID: 17339547)
      J Biol Chem. 2005 Apr 8;280(14):14168-76. (PMID: 15640155)
      Science. 1996 Dec 20;274(5295):2100-3. (PMID: 8953045)
      Nat Genet. 2000 Sep;26(1):81-4. (PMID: 10973254)
      J Biol Chem. 1998 Aug 7;273(32):20156-61. (PMID: 9685360)
      Hypertens Res. 2005 Mar;28(3):255-62. (PMID: 16097370)
      Circ Res. 2001 Mar 30;88(6):555-62. (PMID: 11282888)
      J Biol Chem. 2001 Dec 14;276(50):47650-7. (PMID: 11598137)
      Biochem J. 2001 Jul 15;357(Pt 2):521-7. (PMID: 11439103)
      Circ Res. 2003 May 30;92(10):1162-9. (PMID: 12714563)
      Am J Respir Cell Mol Biol. 2001 Nov;25(5):652-8. (PMID: 11713109)
      N Engl J Med. 2005 Sep 29;353(13):1412-3. (PMID: 16192491)
      J Biol Chem. 2005 Jul 29;280(30):27872-8. (PMID: 15944146)
      J Clin Invest. 2005 Oct;115(10):2811-21. (PMID: 16200212)
      Circ Res. 2003 Aug 22;93(4):e38-47. (PMID: 12881480)
      J Biol Chem. 2004 Nov 12;279(46):47626-32. (PMID: 15339912)
      Am J Physiol Heart Circ Physiol. 2006 Jan;290(1):H390-7. (PMID: 16155101)
      Eur Respir J. 1998 Mar;11(3):554-9. (PMID: 9596101)
      Mol Cell Biol. 2007 Feb;27(3):803-17. (PMID: 17101779)
      J Biol Chem. 2003 Dec 19;278(51):51340-6. (PMID: 14534304)
      J Biol Chem. 2003 Apr 4;278(14):11945-53. (PMID: 12551936)
      J Immunol. 2005 May 1;174(9):5490-8. (PMID: 15843547)
      Circulation. 2002 Jan 29;105(4):516-21. (PMID: 11815437)
      Arterioscler Thromb Vasc Biol. 2003 Dec;23(12):2172-7. (PMID: 14551159)
    • Grant Information:
      United Kingdom BHF_ British Heart Foundation; T32 HL007708 United States HL NHLBI NIH HHS; 2-T32-HL007708-14 United States HL NHLBI NIH HHS; R01 HL074186 United States HL NHLBI NIH HHS; R01 HL087118 United States HL NHLBI NIH HHS; 1-R01-HL074186-01 United States HL NHLBI NIH HHS
    • Accession Number:
      0 (Apolipoproteins E)
      0 (BMP2 protein, human)
      0 (Bmp2 protein, mouse)
      0 (Bone Morphogenetic Protein 2)
      0 (Bone Morphogenetic Proteins)
      0 (Hypoglycemic Agents)
      0 (PPAR gamma)
      0 (Platelet-Derived Growth Factor)
      0 (Proto-Oncogene Proteins c-sis)
      0 (Thiazolidinediones)
      0 (Transforming Growth Factor beta)
      05V02F2KDG (Rosiglitazone)
      1B56C968OA (Becaplermin)
      EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
      EC 2.7.11.30 (Bone Morphogenetic Protein Receptors, Type II)
    • Publication Date:
      Date Created: 20080403 Date Completed: 20080701 Latest Revision: 20221109
    • Publication Date:
      20221213
    • Accession Number:
      PMC2276393
    • Accession Number:
      10.1172/JCI32503
    • Accession Number:
      18382765